Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
GLP1 agonist therapy may be used to address medically supervised weight reduction, obesity-related comorbidities, and longer-term weight management in appropriately evaluated patients
Our members lose an average of 2st 3lb by month 6
NICE guidance, 4 September 2023: 2 Tirzepatide for managing overweight and obesity
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar
US$ 29.16
US$ 24.47
US$ 29.42
US$ 22.12
